You are here:  

• Print

Economics

WP1: Measuring serious harm, and economic impact, associated with hazardous prescribing

• Determine the risk of serious harm, and economic impact, associated with hazardous prescribing
• Develop the economic models that will be used to evaluate the cost-effectiveness of the interventions in WP2 and WP3

Five sets of economic models to be built

• Outcome 1: gastrointestinal bleeds (models GI1-GI6)
• Outcome 2: exacerbation of asthma (models EA1-EA2)
• Outcome 3: heart failure from NSAIDs (model HF1)
• Outcome 4: stoke from antipsychotics (model ST1)
• Outcome 5: acute kidney injury from NSAIDs (model KI1)

WP2: Evaluating prescribing safety indicators embedded in computerised clinical decision support

• To determine the effectiveness and cost effectiveness of the CDS-software, OptimiseRx, in reducing hazardous prescribing in general practices

WP3: Evaluating a large-scale rollout of the PINCER intervention

• To evaluate the cost-effectiveness of a pharmacist-led IT-based intervention (PIINCER) when widely implemented in general practices

Economics team members

• Professor Rachel  Elliott (lead)
• Elizabeth Camacho
• Georgios Gkountouras 
• Thomas Allen
• Vasiliki Xenelli
• Leonie Brinkmann